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Purpose/Objective: So far risk stratification and treatment 
decisions in the management of prostate cancer patients are 
based on T stage, Gleason score and PSA value. Currently 
used risk classifications often lead to under- or 
overtreatment. Other parameters to better characterize 
prostate cancer and guide the treatment are urgently 
needed. Therefore we conducted a study correlating miRNA 
expression levels with outcome data. 
Materials and Methods: MiRNA expression levels of eight 
hundred miRNAs of forty three patients who had undergone 
salvage radiation therapy following biochemical failure were 
analyzed using the nCounter human v2 assay (NanoString 
Technologies; Seattle, WA). Formalin-fixed, paraffin-
embedded tissue blocks were used. Expression data were 
correlated with biochemical relapse free survival. Univariate 
and multivariate Cox proportion hazards regression models as 
well as receiver operating characteristics were utilized to 
identify statistically significant miRNAs 
Results: Eighty eight miRNAs were identified to be 
significantly (p36 months). Nine miRNAs were identified to be 
significantly (p 
Conclusions: miRNA signatures can distinguish patients with 
early versus late recurrence after prostatectomy. Two novel 
miRNAs were identified that significantly improve prediction 
of biochemical failure post-salvage radiation therapy 
compared to available clinico-histopathological factors alone, 
supporting the use of miRNAs within clinically used predictive 
models. Both findings warrant further validation studies. 
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Purpose/Objective: Toxicity related to the gastrointestinal 
(GI) and genitourinary GU tract following radiotherapy (RT) 
for prostate cancer involves the interplay between various 
symptoms. The purpose of this study was to investigate the 
robustness of patient-reported symptoms over time to follow-
up within identified symptom groups. 
Materials and Methods: The investigated subjects were 
previously treated in a clinical trial (to explore the toxicity 
and efficacy of pelvic lymph node RT) with intensity-
modulated RT for locally advanced prostate cancer in 2011-
2012 (N=87). Prescribed dose was 78 Gy to the prostate and 
56 Gy to the pelvic lymph nodes in 39 fractions. The patients 
completed the study-specific questionnaire at different time 
points within the first year after RT (at 3, 6, and 12 months). 
This study is based on the 18 and 12 GI and GU symptoms, 
respectively, that directly reflected potential RT-induced 
injuries. For both GI and GU toxicity, symptom groups were 
generated based on interacting symptoms as identified by 
factor analysis (FA). The temporal pattern of symptoms in 
these symptom groups was studied within the first year after 
RT. 
Results: Two GI and two GU symptom groups were identified 
at 3, 6, and 12 months post-RT. Based on the symptoms 
included, the GI symptom groups could be labelled as faecal 
Leakage (4-7 symptoms), and Obstruction (3-7 symptoms), 
and the GU symptom groups as urinary Incontinence (3-8 
symptoms), and Obstruction (3-9 symptoms). Two symptoms 
of each symptom group remained present across the 
investigated time-points. 
Conclusions: Our findings indicate that at least two patient-
reported GI and GU symptoms remain present during the first 
year after RT following RT for locally advanced prostate 
cancer in each investigated symptom group. These symptoms 
have the potential to serve as attractive endpoints in 
quantitative dose-response modelling to better understand 
the temporal pattern of RT-induced causes of the GI - and GU 
tract.  
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Purpose/Objective: To retrospectively evaluate overall 
survival (OS), biochemical and metastatic relapse-free 
survival (bRFS and mRFS), late genitourinary and 
gastrointestinal toxicity in patients (pts) treated with 
adjuvant radiotherapy (ART) or salvage radiotherapy (SRT) 
for prostate cancer. We imported all DVH into an in house 
system (PRODVH) to elaborate means and comparisons within 
groups clinically identified. 
Materials and Methods: From 1999 to 2013, 240 pts were 
selected for the analysis (120 pts treated with ART and 120 
pts treated with SRT). The median follow-up was 50,7 
months. bRFS, mRFS and OS were correlated with age, PSA, 
Gleason Score, T and N stage, surgical margins, radiotherapy 
doses and technique, intention to treat (ASTRO guidelines: 
Int J Radiat Oncol Biol Phys. 2013). Toxicity data were 
collected using the RTOG and CTCAE v.4 scales and 
correlated to radiotherapy doses and technique, PTV and 
organ at risk volume. Kaplan-Meyer and Cox regression were 
performed for survivals and Chi Square test were used for 
